Company: RPTX
Filing Date: 2025-01-10
Form Type: 8-K
Source: 0001193125-25-004065
Chunk: 1

Company: Repare Therapeutics Inc.
Filing Date: 2025-01-10
Form: 8-K
Item: Item 7.01
Chunk 1
---
Item 7.01      Regulation FD Disclosure.  

On January 9, 2025, the Company issued a press release announcing a re-alignmentof resources and a re-prioritizationof its clinical portfolio to focus on the continued advancement of its Phase 1 clinical programs, RP-1664andRP-3467, along with an update to its cash position and runway guidance. The Company expects that the consequent savings of its proposed plan to await late-stage clinical funding combined with planned future cost and headcount reductions will extend the Company’s cash runway into mid-2027. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form8-Kand is incorporated herein by reference.